4.2 Article

An evaluation of CD39 as a novel immunoregulatory mechanism invoked by COPD

Journal

HUMAN IMMUNOLOGY
Volume 77, Issue 10, Pages 916-920

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2016.07.007

Keywords

AECOPD; CD39; COPD; IFN gamma; T-cell

Categories

Funding

  1. Ada Bartholomew Medical Research Trust Grant from the Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia
  2. Royal Perth Hospital

Ask authors/readers for more resources

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are characterized by increased pulmonary and systemic inflammation and commonly caused by bacterial and/or viral infection. Little is known about the T-cell dysregulation in AECOPD that promotes these outcomes. CD39 is an ectonucleotidase able to hydrolyse adenosine triphosphate to create adenosine that may inhibit T-cell responses in patients with AECOPD. Here T-cell expression of CD39 measured by flow cytometry was higher in AECOPD patients than stable COPD patients or healthy controls. Higher expression of CD39 was associated with higher levels of plasma soluble tumor necrosis factor receptor but lower interferon-gamma (IFN gamma) levels in supernatants from staphylococcal enterotoxin-B stimulated peripheral blood mononuclear cells. This links increased expression of CD39 with systemic inflammation and impaired T-cell responses (e.g. IFN gamma). The blockade of CD39 pathways may be a novel approach to the control of AECOPD, reducing the dependency on antibiotics. (C) 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available